Vitrolife ahead of Q3: We expect Vitrolife to extend the consolidation period - Redeye

Vitrolife is going through a period with softer organic growth in the 3-6% which compares with a more typical 8-11% strict organic growth for Vitrolife, in our view. Consumables are likely to perform, and the main uncertainty and also our main near-term interest relates to Genetic Services and Vitrolife’s ability to stabilize and improve the growth rate.

Länk till analysen i sin helhet: https://www.redeye.se/research/950227/vitrolife-ahead-of-q3-we-expect-vitrolife-to-extend-the-consolidation-period?utm_source=finwire&utm_medium=RSS